Abstract

Revolution Medicines released Phase 2 data in April 2026 showing that daraxonrasib produced clinically meaningful responses in pancreatic cancer patients harboring KRAS mutations, a population for which systemic therapy has historically yielded poor outcomes. The results arrived alongside a broader expansion of RAS-directed inhibitor programs across the oncology drug development field. Concurrently, Novo Nordisk reported positive Phase 3 findings for etavopivat, an experimental oral agent targeting sickle cell disease, and Eli Lilly moved toward a reported acquisition of Kelonia Therapeutics, a privately held developer of in-vivo chimeric antigen receptor T-cell therapies, for more than $2 billion. Taken together, the week’s data represent a period of notable activity across oncology, hematology, and cell therapy. Each program carries distinct methodological strengths and limitations that warrant careful evaluation before broad clinical adoption is considered appropriate.

---

Pancreatic ductal adenocarcinoma kills roughly 55,000 Americans each year. Median survival after diagnosis with metastatic disease sits below 12 months for most patients. Those two figures have not moved substantially in decades.

That context is necessary to appreciate what Revolution Medicines reported last week.

The company released results from a study of daraxonrasib, its RAS(ON) multi-selective inhibitor, in patients with KRAS-mutant pancreatic cancer. The data, covered by STAT News, drew attention not because a single drug cured a hard cancer, but because KRAS has resisted every serious pharmaceutical attempt to neutralize it for more than four decades. Getting any drug to bind reliably to the KRAS protein and interrupt downstream signaling has confounded oncologists and medicinal chemists since the oncogene’s discovery. Daraxonrasib, according to Revolution Medicines, appears to do exactly that across multiple KRAS mutation subtypes.

The protein itself is the problem. KRAS is small. Its surface is smooth, offering few pockets where a small molecule can bind and stay. Early efforts to drug it directly failed repeatedly. For years, oncologists instead targeted downstream effectors, with mixed and generally disappointing results. It wasn’t until Amgen’s sotorasib received U.S. Food and Drug Administration approval in 2021 for KRAS G12C-mutant non-small cell lung cancer that the field got its first proof that direct KRAS inhibition was pharmacologically achievable. G12C, though, represents only one substitution in a protein that acquires mutations at multiple codons across different tumor types.

Pancreatic cancer, particularly.

KRAS mutations appear in approximately 90% of pancreatic ductal adenocarcinomas. G12C accounts for a small fraction of those. G12D and G12V predominate. Daraxonrasib targets multiple KRAS mutation subtypes simultaneously, which is the mechanistic distinction that makes the Revolution Medicines data notable rather than merely incremental.

The study design matters here. The current data come from an early-phase setting. That’s a meaningful constraint on the conclusions any clinician should draw. Response rates in heavily pre-treated populations don’t translate directly into survival benefit at the population level, and the sample sizes involved don’t support the kind of subgroup analysis that would let oncologists match patient mutation profiles to predicted response with confidence. Revolution Medicines has not yet reported mature overall survival data. Those numbers will determine whether daraxonrasib changes practice.

What the data did show, and what the field has been waiting years to see, is evidence of clinical activity in a histology where RAS inhibitors have been essentially inactive. The objective response rate, the duration of responses, and the disease control rate across mutation subtypes all suggested that the drug is engaging its target and producing downstream consequences that matter to patients. “We’re finally seeing what cracking this target can look like in a tumor type where patients have had almost nothing,” one oncologist told STAT News in coverage of the release. It’s a sentiment that doesn’t overstate the data but reflects how long the field has waited.

That said, the revolution in RAS pharmacology didn’t happen overnight. It’s the product of structural biology advances, fragment-based drug screening, and covalent chemistry methods that took two decades to mature. The National Cancer Institute’s RAS Initiative, launched in 2013, coordinated basic science efforts across academic and government labs and directly accelerated the identification of allosteric binding sites that earlier screening campaigns had missed. Revolution Medicines’ approach draws on many of those foundational insights while extending them toward pan-RAS selectivity.

The competitive implications are substantial. Mirati Therapeutics, now part of Bristol Myers Squibb following a 2024 acquisition, has adagrasib, approved in the G12C-mutant lung cancer setting. Merck has combination programs pairing its KRAS-directed agents with SHP2 inhibitors in an attempt to blunt feedback reactivation, which remains a known mechanism of resistance even when initial responses are achieved. Revolution Medicines itself is running parallel programs targeting RAS(ON) in lung and colorectal cancer. If daraxonrasib’s early pancreatic cancer data hold up in larger cohorts, the company will be managing one of the most closely watched oncology development programs in the field.

Resistance, when it comes, is the real scientific question. Prior RAS inhibitors have demonstrated that tumor cells are exceptionally good at finding workarounds. Amplification of upstream drivers, secondary mutations in RAS itself, and bypass signaling through parallel pathways have all appeared in patients treated with G12C-specific agents. Whether a multi-selective inhibitor like daraxonrasib delays or displaces those resistance mechanisms, or simply produces a different pattern of acquired resistance, won’t be knowable until substantially more patients have been treated and followed.

---

The sickle cell data from Novo Nordisk landed the same week.

Etavopivat, an oral pyruvate kinase activator, met both the primary endpoint of vaso-occlusive crisis reduction and the secondary endpoint of hemoglobin response in a Phase 3 randomized controlled trial (RCT). Sickle cell disease affects approximately 100,000 patients in the United States, the majority of them Black Americans, a population historically underrepresented in clinical trials for the condition despite bearing most of its morbidity. That demographic reality means the Phase 3 results carry public health weight beyond the pharmacological finding alone.

Etavopivat works by activating pyruvate kinase R in red blood cells, shifting their metabolic state and reducing sickling under hypoxic conditions. Mitapivat, a related compound from Agios Pharmaceuticals, has already received FDA approval for pyruvate kinase deficiency and has shown early signals in sickle cell disease in smaller studies. Etavopivat’s Phase 3 success in sickle cell, if confirmed by regulatory review, would represent the first oral disease-modifying therapy in that indication to succeed in a large RCT since hydroxyurea established its role in the 1990s. That’s a long gap. The limitations are real: the trial population, the duration of follow-up, and the precise pain crisis reduction magnitude all require scrutiny before etavopivat’s place relative to crizanlizumab, voxelotor, or the more recent gene therapy approvals can be established.

---

Eli Lilly’s reported move toward acquiring Kelonia Therapeutics for more than $2 billion, as described by the Wall Street Journal, fits a pattern the company has followed aggressively since 2023. The deal hasn’t closed. No definitive agreement had been announced as of April 20, 2026. But if completed, it would give Lilly a foothold in in-vivo CAR-T therapy, an approach that programs a patient’s own T-cells inside the body using viral vectors rather than the ex-vivo manufacturing process that has made conventional CAR-T therapies logistically complex and expensive. Kelonia’s lead program is in early-stage investigation for multiple myeloma. The science is early. The valuation reflects what the modality could become if the manufacturing and delivery problems that currently limit in-vivo cell engineering are resolved, not what it has demonstrated in patients so far.

The board-level departure at Helus Pharma, where CEO Michael Cola resigned “at the request of the board of directors” and was replaced on an interim basis by Chairman Eric So, is the kind of executive transition that sometimes precedes a strategic shift in a company’s development direction and sometimes reflects simpler governance disagreements. Helus develops psychedelics-based therapies for depression. The company did not characterize the reason for the request publicly, which is consistent with standard practice but does not help external observers assess what it signals about the company’s pipeline status or near-term trajectory.

---

The Breakthrough Prize Foundation recognized researchers for advances in gene therapy and ALS genetics during the same period, a reminder that the foundational science underlying commercial drug development programs continues to generate findings that precede clinical translation by years. Gene therapy’s progress from experimental modality to approved therapeutic across multiple rare disease indications over the past decade has been substantial, though the cost and manufacturing complexity of vector-based treatments continue to constrain access, particularly in lower-income settings and among underserved patient populations in the United States. The ALS genetics work rewarded by the prize reflects sustained basic science investment in a disease for which disease-modifying therapy remains limited despite decades of effort.

Across these developments, the common thread is time. Daraxonrasib’s early results reflect four decades of failed attempts at KRAS. Etavopivat builds on red cell biology research that has accumulated since the molecular basis of sickling was established in the mid-twentieth century. In-vivo CAR-T platforms are the product of two decades of synthetic immunology. The Breakthrough Prize honorees built on foundational discoveries that preceded their own work by years or longer. Each program carries the weight of that accumulated effort, and each also carries the uncertainty that attaches to any finding before it has been replicated, confirmed in larger populations, and subjected to the kind of independent scrutiny that distinguishes durable clinical knowledge from provisional optimism.